Radioligand Production

Every batch goes through rigorous quality checks to ensure it’s safe and works as intended. The medicine is only released for use after it passes all tests, guaranteeing that patients receive high-quality treatment.

After the radioactive isotope is made, it’s combined with a targeting molecule, the ligand, in a lab. For prostate cancer, this molecule might be one that finds PSMA on cancer cells. Together, they form the complete radioligand therapy drug. The drug is made in specialized laboratories under strict rules. Every batch goes through rigorous quality checks to ensure it’s safe and works as intended. Scientists test that the dose has the right strength and purity. Regulators, like the FDA in the U.S., set standards that each dose must meet. The medicine is only released for use after it passes all tests, guaranteeing that patients receive high quality treatment. Because the medicine is radioactive, the clock is ticking after production. The team schedules production carefully so that as soon as the dose is ready and approved, it moves quickly into the next stage, packaging and shipping to reach patients in time.